Prisma Health-Upstate

1. Seattle Genetics, Inc. $373,707 73 payments
2. InspireMD Ltd $170,363 3 payments
3. Arthrex, Inc. $66,409 3 payments
4. Global Blood Therapeutics, Inc. $46,460 2 payments
5. Medtronic, Inc. $39,125 7 payments
6. Contego Medical, Inc $19,188 4 payments
7. Merck Sharp & Dohme Corporation $435 1 payment

1. A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) $196,812 6 payments
2. A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations $124,037 38 payments
3. Safety and Efficacy of the CGuard Carotid Stent System in Carotid Artery Stenting $73,896 1 payment
4. LIMIT Study: Lateralization after IntraMedullary nailing of InterTrochanteric Hip Fractures $66,409 3 payments
5. Safety and Efficacy of the CGuard Carotid Stent System in Carotid Artery Stenting (C-Guardians) $49,674 1 payment
6. Safety and Efficacy of the CGuard Carotid Stent System in Carotid Artery Stenting $46,793 1 payment
7. Gbt_440-041_3939_01 $46,460 2 payments
8. Shield US PAS $39,125 7 payments
9. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SGN-35 and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant $27,924 2 payments
10. Performance II $19,188 4 payments

1. Other $73,896 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.